Company intelligence / Profile preview

Mindstate Design Labs

South San Francisco, California, United Statesmindstate.design ↗

Ownership: Private
Employees: ~7
Development stage: Phase 1

Overview

Mindstate Design Labs uses its proprietary Osmanthus AI platform to map the biochemical underpinnings of emotional and cognitive states by analyzing over 60–70k human reports of psychoactive drug effects. Its lead asset MSD‑001 (based on the molecule 5-MeO-MiPT/"moxy") aims to induce rapid emotional/cognitive flexibility without hallucinations. The company has submitted an IND application for clinical trials of this compound. Early results focus on demonstrating precision design of therapeutic mental/emotional states; no published clinical efficacy data yet.

Therapeutic areas: Psychiatry
Modalities: Small molecules (psychedelic-inspired compounds)AI-designed psychoactive agents
Industry: Biotech

Drug pipeline

1 asset

MSD-001

Beyond the preview

Go deeper on Mindstate Design Labs.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mindstate Design Labs.

Explore the full profile